Veru has secured FDA feedback clearing a defined regulatory path for enobosarm, a selective androgen receptor modulator, as an add-on to GLP-1 receptor agonists in obesity. The agency indicated that incremental weight loss versus GLP-1 therapy alone is an acceptable primary endpoint for approval and confirmed 3 mg as an appropriate dose for further development. The FDA also encouraged inclusion of younger adults alongside older patients. Veru plans a 180-patient Phase 2b “plateau” study in individuals initiating tirzepatide, with percent change in body weight at 72 weeks as the primary endpoint and body composition and physical function as key secondaries, targeting a start in the first quarter of 2026, subject to financing.
The signal here is larger than a single program. Regulators appear to be carving out a combination pathway in obesity that rewards incremental efficacy on top of GLP-1 backbones, not just improvements in body composition. If that stance holds, it could catalyze a new class of adjunctive agents designed to extend and deepen weight loss while mitigating the muscle loss that is increasingly scrutinized in real-world GLP-1 use. The strategic question now is who will own this add-on layer: the GLP-1 incumbents, or smaller biopharmas able to show persuasive, regulator-aligned evidence?
Why this matters now is the plateau problem. In pivotal data sets, a large majority of GLP-1–treated patients hit a weight-loss ceiling by roughly 72 weeks, with many still overweight or obese at that point. Veru bets that preserving lean mass and physical function can sustain energy expenditure and enable further fat loss, effectively resetting that plateau. In its prior 16-week study with semaglutide, enobosarm was associated with preserved lean mass, additional fat loss, and improved function, and during a maintenance phase after semaglutide discontinuation, it reduced weight regain relative to placebo. For older adults in particular, muscle preservation is not just cosmetic; it ties to mobility, fall risk, and long-term adherence. For HCPs, a credible mechanism to maintain lean mass while continuing fat loss could shift follow-up protocols, DEXA use, and counseling around GLP-1 de-escalation or cycling.
For payers, the FDA’s acceptance of incremental weight loss as a primary endpoint is pivotal because it translates directly into economic models that prize additional kilograms lost and maintained. Still, reimbursement for a chronic combination will hinge on more than the scale. Secondary endpoints—lean mass, function, bone health, and patient-reported outcomes—will need to show meaningful, durable advantages, and health systems will ask whether those translate into fewer falls, hospitalizations, or disability claims. Medical Affairs teams should be planning pragmatic studies and real-world evidence strategies that capture composition and functional outcomes alongside utilization.
Commercially, an effective plateau-breaker could lengthen GLP-1 persistence and increase lifetime value per patient, but it also invites cost-stacking scrutiny and step-editing. Business development will be central: securing tirzepatide supply for trials, aligning with obesity centers of excellence, and potentially partnering with GLP-1 holders seeking to protect franchise durability. Competitive pressure is mounting as large players explore multi-hormonal combinations and muscle-preserving approaches, including myostatin/ActRII pathway agents, aiming to own both magnitude and quality of weight loss.
The next test is whether 72-week data can show additive, clinically meaningful weight loss with preserved lean mass in a mixed-age population. If it does, the obesity market could pivot from monotherapy to regimen-based care with GLP-1s as a backbone and composition modulators layered on top. Will regulators and payers formalize this adjunct standard—and who will be first to lock in a reimbursable label that defines the bar for every follower?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
